The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.
 
Alessia D'Alonzo
No Relationships to Disclose
 
Claudia Bighin
No Relationships to Disclose
 
Fabio Puglisi
No Relationships to Disclose
 
Michelino DeLaurentiis
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
Research Funding - Novartis; Roche
 
Andrea Fontana
No Relationships to Disclose
 
Palma Pugliese
No Relationships to Disclose
 
Grazia Arpino
Honoraria - Celgene; Roche
Consulting or Advisory Role - Celgene; Novartis; Pfizer; Roche
Research Funding - Eisai; Novartis
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Francesca Poggio
No Relationships to Disclose
 
Marina Vaglica
No Relationships to Disclose
 
Chiara Dellepiane
No Relationships to Disclose
 
Eva Blondeaux
No Relationships to Disclose
 
Benedetta Conte
No Relationships to Disclose
 
Francesco Cognetti
No Relationships to Disclose
 
Ornella Garrone
Research Funding - Eisai (Inst)
 
Simona Pastorino
No Relationships to Disclose
 
Marcello Ceppi
No Relationships to Disclose
 
Lucia Del Mastro
No Relationships to Disclose